TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: NCS positivity in patients with rheumatic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrent urinary incontinence (UI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent stress urinary incontinence (SUI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stress-induced blood pressure reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interobserver agreement for grating acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement for letter acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problems during device removal
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of L reuteri in stool samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss posttreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of atrial fibrillation after open heart surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DENV-2 NS1-specific IgG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inhibition of NS1-induced hyperpermeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GC-IPL thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peripapillary VD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peripapillary PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ipsilateral superior shift of the condyle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ipsilateral lateral shift of the condyle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ipsilateral anterior shift of the condyle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of Bone Turnover Markers (BTM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBU score at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Differentially Expressed Genes (DEGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of ipsilateral breast recurrences
Endpoint domain: Mortality/survival
Primary endpoint: Maximum % PNIF fall from baseline after nasal AMP challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the 60-min time-response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total nasal symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major systemic embolism or death from vascular causes
Endpoint domain: Mortality/survival
Primary endpoint: MADRS total score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery of stimulus detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shift in the visual field border
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of decayed teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum inorganic fluoride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: uptake of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degradation rate of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAFLD mean score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous analgesia at 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the fasciae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days for removal of the drain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total volume of tissue fluids upon drain removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rates at the donor site
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: total cotinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: carbon monoxide boost/cig
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in continence grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pad weight testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevation in aqueous flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate and vigorous physical activity as a proportion of accelerometer wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate of dislocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum serum concentration of morphine (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repigmentation after full surface ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma levels of s4‐1BB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of swollen joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28‐CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of ACTH, ADH, and cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma concentrations of noradrenaline and dopamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of potentially inappropriate medication (PIM) use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-adjusted life year (QALY)
Endpoint domain: Resource use
Primary endpoint: Peristalsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse drug reactions (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Feel Drug ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Seizure burden (SB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Performance scores on BSID III
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postprandial PP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postprandial PYY concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: S100b levels at the end of bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of growth of violence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum IgA, IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pulmonary arterial pressure (PPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Microshear bond strength values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative morphine consumption at 48 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative stent thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygenation index (PaO(2)/FIO(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Average cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Residual muscle paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Time from end of surgery to tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 26Mg absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak isotope enrichment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the enrichment vs time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet reactivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exclusive MBM use at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any MBM use at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central corneal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impaired adrenal function
Endpoint domain: Adverse events/effects
Primary endpoint: Gram-negative pancreatic infection
Endpoint domain: Adverse events/effects
Primary endpoint: Heel contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of swing phase in the gait cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in paraesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of neurophysiological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bone marrow fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: predialysis serum phosphate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postdialysis serum phosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: phosphate clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to recover to straight and level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roll reversal errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for GD symbology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative postprandial glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Roughness on the Consensus Auditory‐Perceptual Evaluation of Voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time necessary for the creation of pneumoperitoneum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in hematocrit level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in mean units of blood transfused
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in energy level and ability to perform daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Support required to complete the task
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: SPID12 score for postbunionectomy surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corrected HSDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean score of overall symptoms of PMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean score of psychological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children without TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients on target for LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transient hypoparathyroidism
Endpoint domain: Adverse events/effects
Primary endpoint: Transient damage of the recurrent laryngeal nerve
Endpoint domain: Adverse events/effects
Primary endpoint: General Health subscale of the SF‐36
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Timed Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic impairment (EDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: level of performance in final assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of fine-needle aspiration (FNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of fine-needle aspiration (FNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Text quality
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain acceptance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resolution of Metabolic Syndrome (MS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in the number of urgent medical attendances
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: better adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative voice symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to mobilisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triacylglycerol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Remission of erosive reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant plasma n-3 PUFA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant plasma n-6 PUFA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant plasma arachidonic acid (AA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year cumulative incidence of recurrence
Endpoint domain: Mortality/survival
Primary endpoint: urodynamic stress incontinence rate at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of incontinent episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urogenital Distress Inventory and Incontinence Impact Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment Emergent Symptoms (TES)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal creatine kinase (CK) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of any distal adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk of distal advanced adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of diagnostic colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 8-year changes in BMI-SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adrenaline and noradrenaline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reproducibility of horizontal cup/disk ratio measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PES score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: venous ulcer recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduced traumatic stress reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer child depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced family arguing
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Post-mastectomy pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of freezing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time in new zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: physical and social functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Likelihood of gaining/retaining employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: serum levels of pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: perioperative blood product transfusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prolactin response to FEN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Disease activity remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAMD17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of papules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of pustules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: level of suicidal ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximal swings in glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of major complications
Endpoint domain: Mortality/survival
Primary endpoint: microvascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: reported pain levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Competency in motivational interviewing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uterine contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary events (coronary heart disease death, nonfatal myocardial infarction, resuscitated cardiac arrest, fatal or nonfatal stroke)
Endpoint domain: Mortality/survival
Primary endpoint: Composite of death, myocardial infarction, and recurrent ischemia
Endpoint domain: Mortality/survival
Primary endpoint: pain of needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anesthetic infiltration pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain of suturing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median log‐fold change in Ki‐67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete cell‐cycle arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-back pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIM improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: TUG improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 30-day seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depression severity on PHQ-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum levels of CK‐MB and cTnI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: re‐beat time during CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes